0.0001 0 (0%) | 02-11 15:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1-year : | ||
Resists | First : | Second : | ||
Pivot price | ||||
Supports | First : | Second : | ||
MAs | MA(5) : | MA(20) : | ||
MA(100) : | MA(250) : | |||
MACD | MACD : | Signal : | ||
%K %D | K(14,3) : | D(3) : | ||
RSI | RSI(14): | |||
52-week | High : | Low : |
If tomorrow: | Open lower | Open higher |
High: | - | - |
Low: | - | - |
Close: | - | - |
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
PNK
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | (%) |
Held by Institutions | (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | |
EPS Est Next Qtrly | |
EPS Est This Year | |
EPS Est Next Year | |
Book Value (p.s.) | |
Profit Margin | % |
Operating Margin | % |
Return on Assets (ttm) | % |
Return on Equity (ttm) | % |
Qtrly Rev. Growth | % |
Gross Profit (p.s.) | |
Sales Per Share | |
EBITDA (p.s.) | |
Qtrly Earnings Growth | % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | |
PEG Ratio | |
Price to Book value | |
Price to Sales | |
Price to Cash Flow |
Dividend | |
Forward Dividend | |
Dividend Yield | 0% |
Dividend Pay Date | |
Ex-Dividend Date |